RNA interference (RNAi) has broad potential as a therapeutic to reversibly silence any gene. To achieve the clinical potential of RNAi, delivery materials are required to transport short interfering RNA (siRNA) to the site of action in the cells of target tissues. This Review provides an introduction to the biological challenges that siRNA delivery materials aim to overcome, as well as a discussion of the way that the most effective and clinically advanced classes of siRNA delivery systems, including lipid nanoparticles and siRNA conjugates, are designed to surmount these challenges. The systems that we discuss are diverse in their approaches to the delivery problem, and provide valuable insight to guide the design of future siRNA delivery materials.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Morrissey, D. V. et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotechnol. 23, 1002–1007 (2005).
Okumura, A., Pitha, P. M. & Harty, R. N. ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. Proc. Natl Acad. Sci. USA 105, 3974–3979 (2008).
Alnylam RNAi Roundtable: Conjugate Delivery (2012); http://www.alnylam.com/capella/wp-content/uploads/2012/12/ALNY-RNAiRoundtable-ConjugateDelivery-Dec-14-2012.pdf
Shen, H., Sun, T. & Ferrari, M. Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther. 19, 367–373 (2012).
Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067–1070 (2010).
Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nature Rev. Drug Discov. 8, 129–138 (2009).
Singha, K., Namgung, R. & Kim, W. J. Polymers in small-interfering RNA delivery. Nucleic Acid Therapeut. 21, 133–147 (2011).
Semple, S. C. et al. Rational design of cationic lipids for siRNA delivery. Nature Biotechnol. 28, 172–176 (2010).
Akinc, A. et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nature Biotechnol. 26, 561–569 (2008).
Mo, R. H., Zaro, J. L. & Shen, W.-C. Comparison of cationic and amphipathic cell penetrating peptides for siRNA delivery and efficacy. Mol. Pharm. 9, 299–309 (2012).
Yao, Y. et al. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci. Transl. Med. 4, 130ra48 (2012).
Dassie, J. P. et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nature Biotechnol. 27, 839–849 (2009).
Neff, C. P. et al. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci. Transl. Med. 3, 66ra6 (2011).
Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173–178 (2004).
Thomas, M. et al. Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues. Ann. NY Acad. Sci. 1175, 32–39 (2009).
Hannon, G. J. RNA interference. Nature 418, 244–251 (2002).
Nishina, K. et al. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol. Ther. 16, 734–740 (2008).
Alexis, F., Pridgen, E., Molnar, L. K. & Farokhzad, O. C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505–515 (2008).
Petros, R. A. & DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications. Nature Rev. Drug Discovery 9, 615–627 (2010).
Kanasty, R. L., Whitehead, K. A., Vegas, A. J. & Anderson, D. G. Action and reaction: the biological response to siRNA and its delivery vehicles. Mol. Ther. 20, 513–524 (2012).
Layzer, J. M. et al. In vivo activity of nuclease-resistant siRNAs. RNA 10, 766–771 (2004).
Jackson, A. L. & Linsley, P. S. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nature Rev. Drug Discov. 9, 57–67 (2010).
Nguyen, D. N. et al. Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery. Proc. Natl Acad. Sci. USA 109, E797–E803 (2012).
Deleavey, G. F., Watts, J. K. & Damha, M. J. in Current Protocols in Nucleic Acid Chemistry (ed. Beaucage, S. L. et al.) Ch. 16, Unit 16.3 (2009).
Whitehead, K. A., Dahlman, J. E., Langer, R. S. & Anderson, D. G. Silencing or stimulation? siRNA delivery and the immune system. Annu. Rev. Chem. Biomol. Eng. 2, 77–96 (2011).
Wang, A. Z., Langer, R. & Farokhzad, O. C. Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 63, 185–198 (2012).
Malek, A. et al. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol. Appl. Pharmacol. 236, 97–108 (2009).
Wolfrum, C. et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nature Biotechnol. 25, 1149–1157 (2007).
Akinc, A. et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357–1364 (2010).
Romberg, B., Hennink, W. E. & Storm, G. Sheddable coatings for long-circulating nanoparticles. Pharm. Res. 25, 55–71 (2008).
Bazile, D. et al. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 84, 493–498 (1995).
Jarad, G. & Miner, J. H. Update on the glomerular filtration barrier. Curr. Opin. Nephrol. Hypertens. 18, 226–232 (2009).
Wartiovaara, J. et al. Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. Filtration 114, 1475–1483 (2004).
He, X. M. & Carter, D. C. Atomic structure and chemistry of human serum albumin. Nature 358, 209–215 (1992).
Huang, Y. et al. Elimination pathways of systemically delivered siRNA. Mol. Ther. 19, 381–385 (2011).
Lee, H. et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nature Nanotech. 7, 389–393 (2012).
Rozema, D. B. et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl Acad. Sci. USA 104, 12982–12987 (2007).
Zuckerman, J. E., Choi, C. H. J., Han, H. & Davis, M. E. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc. Natl Acad. Sci. USA 109, 3137–3142 (2012).
Naeye, B. et al. In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier. Biomaterials 34, 2350–2358 (2013).
Aird, W. C. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circul. Res. 100, 158–173 (2007).
Wisse, E., Jacobs, F., Topal, B., Frederik, P. & De Geest, B. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther. 15, 1193–1199 (2008).
Maeda, H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconj. Chem. 21, 797–802 (2010).
Yu, B., Zhao, X., Lee, L. J. & Lee, R. J. Targeted delivery systems for oligonucleotide therapeutics. AAPS J. 11, 195–203 (2009).
Salvati, A. et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nature Nanotech. 8, 137–143 (2013).
Bolhassani, A. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim. Biophys. Acta 1816, 232–246 (2011).
Shim, M. S. & Kwon, Y. J. Stimuli-responsive polymers and nanomaterials for gene delivery and imaging applications. Adv. Drug Deliv. Rev. 64, 1046–1059 (2012).
Schwarz, D. S. et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199–208 (2003).
Jeong, J. H., Mok, H., Oh, Y-K. & Park, T. G. siRNA conjugate delivery systems. Bioconj. Chem. 20, 5–14 (2009).
Davis, M. E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6, 659–668 (2009).
Gonzalez, H., Hwang, S. J. & Davis, M. E. New class of polymers for the delivery of macromolecular therapeutics. Bioconj. Chem. 10, 1068–1074 (1999).
Hwang, S. J., Bellocq, N. C. & Davis, M. E. Effects of structure of beta-cyclodextrin-containing polymers on gene delivery. Bioconj. Chem. 12, 280–290 (2001).
Pun, S. H. et al. Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconj. Chem. 15, 831–840 (2004).
Pun, S. H. & Davis, M. E. Development of a nonviral gene delivery vehicle for systemic application. Bioconj. Chem. 13, 630–639 (2002).
Reineke, T. M. & Davis, M. E. Structural effects of carbohydrate-containing polycations on gene delivery. 1. Carbohydrate size and its distance from charge centers. Bioconj. Chem. 14, 247–254 (2003).
Popielarski, S. R., Mishra, S. & Davis, M. E. Structural effects of carbohydrate-containing polycations on gene delivery. 3. Cyclodextrin type and functionalization. Bioconj. Chem. 14, 672–678 (2003).
Davis, M. et al. Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers. Curr. Med. Chem. 11, 179–197 (2004).
Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E. & Triche, T. J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65, 8984–8992 (2005).
Mishra, S., Heidel, J. D., Webster, P. & Davis, M. E. Imidazole groups on a linear, cyclodextrin-containing polycation produce enhanced gene delivery via multiple processes. J. Control. Release 116, 179–191 (2006).
Bartlett, D. W. & Davis, M. E. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconj. Chem. 18, 456–468 (2007).
Mishra, S., Webster, P. & Davis, M. E. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur. J. Cell Biol. 83, 97–111 (2004).
Bellocq, N. C., Pun, S. H., Jensen, G. S. & Davis, M. E. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconj. Chem. 14, 1122–1132 (2003).
Bartlett, D. W. & Davis, M. E. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 34, 322–333 (2006).
Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A. & Davis, M. E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl Acad. Sci. USA 104, 15549–15554 (2007).
Bartlett, D. W. & Davis, M. E. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol. Bioeng. 99, 975–985 (2008).
Heidel, J. D. et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl Acad. Sci. USA 104, 5715–5721 (2007).
Zimmermann, T. S. et al. RNAi-mediated gene silencing in non-human primates. Nature 441, 111–114 (2006).
Alabi, C., Vegas, A. & Anderson, D. Attacking the genome: emerging siRNA nanocarriers from concept to clinic. Curr. Opin. Pharmacol. 12, 427–433 (2012).
Burnett, J. C., Rossi, J. J. & Tiemann, K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J. 6, 1130–1146 (2011).
Xu, Y. & Szoka, F. C. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 35, 5616–5623 (1996).
Zhang, S., Zhi, D. & Huang, L. Lipid-based vectors for siRNA delivery. J. Drug Target. 20, 724–735 (2012).
Kesharwani, P., Gajbhiye, V. & Jain, N. K. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 33, 7138–7150 (2012).
Huang, L. & Liu, Y. In vivo delivery of RNAi with lipid-based nanoparticles. Annu. Rev. Biomed. Eng. 13, 507–530 (2011).
Sato, Y. et al. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. J. Control. Release 163, 267–276 (2012).
Bottega, R. & Epand, R. M. Inhibition of protein kinase C by cationic amphiphiles. Biochemistry 31, 9025–9030 (1992).
Love, K. T. et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. USA 107, 1864–1869 (2010).
Mahon, K. P. et al. Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery. Bioconj. Chem. 21, 1448–1454 (2010).
Zhang, J., Fan, H., Levorse, D. A. & Crocker, L. S. Ionization behavior of amino lipids for siRNA delivery: determination of ionization constants, SAR, and the impact of lipid pKa on cationic lipid-biomembrane interactions. Langmuir 27, 1907–1914 (2011).
Hafez, I. M., Maurer, N. & Cullis, P. R. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 8, 1188–1196 (2001).
Hafez, I. M., Ansell, S. & Cullis, P. R. Tunable pH-sensitive liposomes composed of mixtures of cationic and anionic lipids. Biophys. J. 79, 1438–1446 (2000).
Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. 51, 8529–8533 (2012).
Zuhorn, I. S. et al. Nonbilayer phase of lipoplex-membrane mixture determines endosomal escape of genetic cargo and transfection efficiency. Mol. Ther. 11, 801–810 (2005).
Zhigaltsev, I. V., Maurer, N., Wong, K. F. & Cullis, P. R. Triggered release of doxorubicin following mixing of cationic and anionic liposomes. Biochim. Biophys. Acta 1565, 129–135 (2002).
Koltover, I. An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science 281, 78–81 (1998).
Belliveau, N. M. et al. Microfluidic synthesis of highly potent limit-size lipid nanoparticles for in vivo delivery of siRNA. Mol. Ther. Nucleic Acids 1, e37 (2012).
Bao, Y. et al. Effect of PEGylation on biodistribution and gene silencing of siRNA/lipid nanoparticle complexes. Pharm. Res. 30, 342–351 (2013).
Kolli, S. et al. pH-Triggered nanoparticle mediated delivery of siRNA to liver cells in vitro and in vivo. Bioconj. Chem. 24, 314–332 (2013).
Lin, S-Y. et al. Sterically polymer-based liposomal complexes with dual-shell structure for enhancing the siRNA delivery. Biomacromolecules 13, 664–675 (2012).
Virtanen, J. A., Ruonala, M., Vauhkonen, M. & Somerharju, P. Lateral organization of liquid-crystalline cholesterol-dimyristoylphosphatidylcholine bilayers. Evidence for domains with hexagonal and centered rectangular cholesterol superlattices. Biochemistry 34, 11568–11581 (1995).
Takahashi, H., Sinoda, K. & Hatta, I. Effects of cholesterol on the lamellar and the inverted hexagonal phases of dielaidoylphosphatidylethanolamine. Biochim. Biophys. Acta 1289, 209–216 (1996).
Sato, Y. et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nature Biotechnol. 26, 431–442 (2008).
Ishiwatari, H. et al. Treatment of pancreatic fibrosis with siRNA against a collagen-specific chaperone in vitamin A-coupled liposomes. Gut 62, 1328–1339 (2013).
Yoshizawa, T., Hattori, Y., Hakoshima, M., Koga, K. & Maitani, Y. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. Eur. J. Pharm. Biopharm. 70, 718–725 (2008).
Feng, C. et al. Silencing of the MYCN gene by siRNA delivered by folate receptor-targeted liposomes in LA-N-5 cells. Ped. Surg. Int. 26, 1185–1191 (2010).
Wan, K. et al. In vivo tumor imaging using a novel RNAi-based detection mechanism. Nanomedicine 8, 393–398 (2012).
Tabernero, J. et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 3, 406–417 (2013).
Alsina, M. et al. Open-label Extension Study of the RNAi Therapeutic ALN-VSP02 in Cancer Patients Responding to Therapy. American Society of Clinical Oncology Meeting (2012); http://www.alnylam.com/capella/wp-content/uploads/2012/06/ALN-VSP-ExtensionStudyPoster-ASCO-June2012-panel.pdf
Wakefield, D. H., Klein, J. J., Wolff, J. A. & Rozema, D. B. Membrane activity and transfection ability of amphipathic polycations as a function of alkyl group size. Bioconj. Chem. 16, 1204–1208 (2005).
Lewis, D. Dynamic polyconjugates (DPC) technology: an elegant solution to the siRNA delivery problem (2006); http://www.arrowheadresearch.com/sites/default/files/udocs/Arrowhead_Research_Corporation-DPC_Technology_White_Paper.pdf
Wong, S. C. et al. Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acid Therapeut. 22, 380–390 (2012).
Macron, D. Arrowhead presents preclinical data on HBV candidate, subcutaneous delivery tech. Gene Silencing News (2012); http://www.arrowheadresearch.com/sites/default/files/news/Gene_Silen_News_111612_reprint.pdf
Rozema, D. B., Ekena, K., Lewis, D. L., Loomis, A. G. & Wolff, J. A. Endosomolysis by masking of a membrane-active agent (EMMA) for cytoplasmic release of macromolecules. Bioconj. Chem. 14, 51–57 (2003).
Wooddell, C. I. et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol. Ther. 21, 973–985 (2013).
Biessen, E. A. et al. Synthesis of cluster galactosides with high affinity for the hepatic asialoglycoprotein receptor. J. Med. Chem. 38, 1538–1546 (1995).
Rensen, P. C., Van Leeuwen, S. H., Sliedregt, L. A., van Berkel, T. J. & Biessen, E. A. Design and synthesis of novel N-acetylgalactosamine-terminated glycolipids for targeting of lipoproteins to the hepatic asialoglycoprotein receptor. J. Med. Chem. 47, 5798–5808 (2004).
Baenziger, J. U. & Fiete, D. Galactose and N-acetylgalactosamine-specific endocytosis of glycopeptides by isolated rat hepatocytes. Cell 22, 611–620 (1980).
Rensen, P. C. et al. Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo. J. Biol. Chem. 276, 37577–37584 (2001).
Kallanthottathil, R. Conjugation strategies for in vivo siRNA delivery (2012); http://www.alnylam.com/capella/wp-content/uploads/2012/11/ALNY-OTS-Conjugate-Oct2012.pdf
Smith, D., Schüller, V., Engst, C., Rädler, J. & Liedl, T. Nucleic acid nanostructures for biomedical applications. Nanomedicine 8, 105–121 (2013).
Shu, D., Shu, Y., Haque, F., Abdelmawla, S. & Guo, P. Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nature Nanotech. 6, 658–667 (2011).
Goodman, R. P. et al. Rapid chiral assembly of rigid DNA building blocks for molecular nanofabrication. Science 310, 1661–1665 (2005).
Xia, W. & Low, P. S. Folate-targeted therapies for cancer. J. Med. Chem. 53, 6811–6824 (2010).
Gindy, M. E., Leone, A. M. & Cunningham, J. J. Challenges in the pharmaceutical development of lipid-based short interfering ribonucleic acid therapeutics. Expert Opin. Drug Deliv. 9, 171–182 (2012).
Chen, D. et al. Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J. Am. Chem. Soc. 134, 6948–6951 (2012).
The authors acknowledge the service to the MIT community of the late Sean Collier.
D.A. has a research grant with Alnylam Pharmaceuticals.
About this article
Cite this article
Kanasty, R., Dorkin, J., Vegas, A. et al. Delivery materials for siRNA therapeutics. Nature Mater 12, 967–977 (2013). https://doi.org/10.1038/nmat3765
Cytocompatibility, membrane disruption, and siRNA delivery using environmentally responsive cationic nanogels
Journal of Controlled Release (2021)
Biomaterials Science (2021)
Biomedical Materials (2021)
Advanced Healthcare Materials (2021)
Robotics, microfluidics, nanotechnology and AI in the synthesis and evaluation of liposomes and polymeric drug delivery systems
Drug Delivery and Translational Research (2021)